Enanta Pharmaceuticals | ENTA - Gewinn Vor Steuern

Aktienkurs
12.69
Täglich Wechseln
0.18 1.44%
Monatlich
-13.97%
Jährlich
104.68%
Q1 Prognose
12.13




Gewinn Vor Steuern Veränderung Datum
AbbVie USD 4.38B 1.92B 2025-09
Amgen USD 3.92B 2.35B 2025-09
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.24B 117M 2025-09
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 557.3M 186.7M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Immunic USD -21.38M 8.2M 2024-06
Incyte USD 389.94M 92.37M 2025-12
Insmed USD -326.93M 41.77M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
J&J USD 4.97B 2.53B 2025-12
Karyopharm Therapeutics USD -30.89M 1.16M 2024-12
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
Merck USD 6.74B 22M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09